Bavarian Nordic A/S, of Kvistgard, Denmark, received a notice of allowance for a patent strengthening protection of Imvamune, its MVA-BN-based smallpox vaccine.

Bolder BioTechnology Inc., of Boulder, Colo., was granted U.S. Patent Nos. 7,148,333 and 7,153,943, which provide protection to its long-acting granulocyte macrophage colony-stimulating factor analogs.

Can-Fite BioPharma Ltd., of Petach Tikva, Israel, received one patent covering CF101 for the treatment of rheumatoid arthritis and a second patent securing exclusive rights to drugs that target the A3 adenosine receptor, including the CF101 and CF102 drugs for cancer.

CardioVascular BioTherapeutics Inc., of Las Vegas, was granted a patent, titled "Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis." It covers the production of FGF-1, its delivery via direct injection into the heart muscle and the therapeutic use.

CEL-SCI Corp., of Vienna, Va., received a notice of allowance for a patent protecting AdapT (Antigen Directed Apoptosis), a T-cell modulation platform technology for treating a number of diseases, such as autoimmune disease, asthma, allergy and transplant rejection.

Cytogen Corp., of Princeton, N.J., was granted U.S. Patent No. 7,135,457, covering its oral drug delivery agents described as random peptide compositions that bind to gastrointestinal transport receptors.

Dyax Corp., of Cambridge, Mass., received U.S. Patent No. 7,153,829, covering methods for preventing or reducing perioperative blood loss during surgery by administering DX-88 (ecallantide), a kallikrein inhibitor. The company also received U.S. Patent No. 7,064,107, which covers methods for preventing or reducing hyperfusion injury with DX-88.